Related Experiment Video
Updated: May 8, 2026
07:23
Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice
Published on: December 20, 2024
Esthesioneuroblastoma in an HIV-1 Infected Patient: Case Report
Enrico Maria Trecarichi1, Jacopo Galli, Enrica Tamburrini
1Institutes of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
Skull Base Reports
|August 29, 2013
Summary
Esthesioneuroblastoma (ENB), a rare nasal tumor, is typically treated with surgery and radiation. Minimally invasive endoscopic resection shows promise for early-stage ENB, especially in immunocompromised patients.
Area of Science:
- Oncology
- Otorhinolaryngology
- Infectious Diseases
Background:
- Esthesioneuroblastoma (ENB) is a rare malignant tumor originating from the nasal cavity's neuroepithelium.
- Current standard treatment involves surgery and radiotherapy.
- Minimally invasive endoscopic resection (MIER) is emerging as a viable option for early-stage ENB.
Purpose of the Study:
- To report the first case of ENB in a patient coinfected with HIV-1 and HCV.
- To discuss treatment strategies and prognosis for ENB, particularly in the context of viral coinfection.
Main Methods:
- Case report detailing a young adult male with ENB, HIV-1, and HCV coinfection.
- Review of existing literature on ENB treatment and outcomes.
Main Results:
- The case highlights the occurrence of ENB in an HIV/HCV coinfected individual.
- Discussion emphasizes the potential of MIER combined with radiotherapy for early-stage ENB, even in complex patient profiles.
Conclusions:
- Esthesioneuroblastoma management requires tailored approaches, especially in coinfected patients.
- MIER offers a potentially less invasive alternative for select early-stage ENB cases, warranting further investigation.
